Best Drug Delivery Companies in United States
The 477 best Drug Delivery companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Intarcia.
The 477 Drug Delivery companies tracked here in the United States represent one of biopharma's most capital-intensive frontiers, ranked by disclosed equity funding and recent funding momentum across a sector that's collectively raised $10.6 billion. Scale that against a global market forecast to reach $2,664.3B by 2027, compounding at 12.02% annually, and you start to feel why the funding keeps coming. ReCode Therapeutics leads individual raises at $342M, with Enable Injections close behind at $304M. Insulet Corp, though, is the revenue story that matters: $2.7B in filed revenue, up 30% year-over-year, running 217 times the sector's median net income of $420,000. Xeris Pharmaceuticals posted the sharpest growth in the cohort at +380% YoY. Median revenue across 16 filers sits at roughly $2M, with a combined pool of $3.0B, so the distribution is steep and worth understanding before you draw any conclusions about the "typical" company here.
What's pulling capital in? As shown in 2020 research, biologics and formulation complexity are driving device innovation in ways that weren't anticipated even five years ago. Government regulations remain a structural drag, delaying timelines and compressing margins at the smaller end of the market. I'd watch that median revenue growth of -3% YoY closely: it tells you the middle of this sector is under pressure even as the outliers compound hard. So the opportunity, if you're mapping this space, is concentrated and uneven, exactly the kind of market where knowing who actually files revenue figures separates signal from noise.
- Rapid Drug Delivery Solution: Enhance Pharmacy’s Services With Mobile
Ranked: Best Drug Delivery companies in United States
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Intarcia 🦄 Provider of osmotic pump for subcutaneous drug delivery | $1.9B | 77 mo ago | Series J | 2 | 1995 | — | — | — |
| 2 | Halozyme Developer of drug delivery technologies for the treatment of various diseases | $1.3B | 46 mo ago | Public | 373 373 → 536 (+44%) · sector median +34% | 1999 | 32 signals ▼32% Earnings · M&A · Funding | 715 patents Enabling subcutaneous delivery of biologics via hyaluronidase and advanced injector devices | 1 partnership |
| 3 | ReCode Therapeutics Developer of precision medicines for treating lung related diseases 67Funding top 17%Talent top 28%Moat top 31%Market top 42% All 7 signals ▾Fundingtop 17% Talenttop 28% Moattop 31% Markettop 42% Newstop 45% Techtop 48% Globalbottom 39% Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $342M | 8 mo ago | Series B | 105 | 2015 | — | — | — |
| 4 | Lyndra Developer of oral drug delivery formulations | $305M | 30 mo ago | Deadpooled | 107 | 2015 | — | 51 patents Patents concentrated in health & consumer products | — |
| 5 | Enable Injections Provider of a wearable drug delivery solution 76Funding top 17%Patents top 23%Innovation top 26%Growth top 26% All 10 signals ▾Fundingtop 17% Patentstop 23% Innovationtop 26% Growthtop 26% Moattop 26% Techtop 42% Markettop 46% Talentbottom 49% Globalbottom 44% Newsbottom 27% Funding: Raised $304M across 10 rounds · 10 rounds over 15 yrs (0.7/yr) Patents: 219 patents matched (strict assignee match) · 109 filings since 2022 vs 93 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $304M | 5 mo ago | Series C | 166 166 → 223 (+34%) · sector median +34% | 2010 | — | 219 patents Handheld injection and fluid transfer devices with safety locking and site monitoring | — |
| 6 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | Public | 88 | 2007 | — | 277 patents siRNA therapeutics and nanoparticle delivery systems for cancer and viral diseases | 1 launch |
| 7 | Elektrofi Digital platform transforming the delivery of biologic medicines | $152M | 22 mo ago | Acquired | 62 | 2016 | 5 signals ▲400% M&A | 81 patents Dry pharmaceutical particle manufacturing for drug delivery via continuous droplet formation. | 4 job openings |
| 8 | OptiNose Developer of smart devices for nasal drug delivery | $120M | 25 mo ago | Acquired | 132 | 2000 | — | 45 patents Intranasal drug delivery devices and formulations for targeted nasal administration | — |
| 9 | Biora Therapeutics Developer of smart pills for targeted drug delivery to treat gastrointestinal diseases | $117M | 30 mo ago | Public | 54 | 2010 | — | — | — |
| 10 | BlueWillow Biologics Pioneering intranasal vaccines for infectious disease and pandemic preparedness | $104M | 28 mo ago | Series C | 9 | 1996 | — | 25 patents Nanoemulsion-based vaccine and antimicrobial delivery systems for mucosal and injectable use | — |
| 11 | Strand Therapeutics Provider of platform to deliver mRNA therapeutics for multi functional treatments 64Growth top 13%Funding top 24%Moat top 31%News top 41% All 7 signals ▾Growthtop 13% Fundingtop 24% Moattop 31% Newstop 41% Talenttop 41% Globalbottom 39% Marketbottom 38% Growth: Headcount 16 → 47 (+194%) across vintages · Fresh capital in last 24 mo Funding: Raised $103M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $103M | 12 mo ago | Series B | 47 | 2017 | — | — | 2 awards |
| 12 | Credence MedSystems Developer of smart devices for drug delivery | $100M | 18 mo ago | Series D | 20 20 → 13 (-35%) · sector median +34% | 2011 | — | 262 patents Safety-engineered syringes and multi-site micro-dose injection devices. | — |
| 13 | Stylus Medicine Developer of gene-based therapeutics for multiple diseases | $85M | 13 mo ago | Series A | 21 | 2022 | — | — | — |
| 14 | TriSalus Life Sciences Developer of drug delivery devices to treat cancers | $72M | 13 mo ago | Public | 100 100 → 128 (+28%) · sector median +34% | 2009 | 11 signals Earnings · Leadership · Announcements | 113 patents Patents concentrated in chemistry & materials | — |
| 15 | Shasqi Developer of local drug activation technology for tumors | $60M | 21 mo ago | Series B | 8 | 2015 | — | 5 patents Bioorthogonal chemical reagents for selective in‑vivo labeling and drug delivery | 1 job opening · 1 launch |
| 16 | Clene Nanomedicine Developer of therapeutics for the treatment of neurodegenerative diseases 29Funding top 29%Patents top 36%Tech top 41%Innovation top 47% All 10 signals ▾Fundingtop 29% Patentstop 36% Techtop 41% Innovationtop 47% Growthbottom 49% Moatbottom 44% Globalbottom 42% Marketbottom 32% Newsbottom 32% Fin. healthbottom 15% Funding: Raised $59.1M across 8 rounds · 8 rounds over 7 yrs (1.1/yr) Patents: 78 patents matched (strict assignee match) · 10 filings since 2022 vs 60 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $59M | 20 mo ago | Public | 99 | 2012 | — | 78 patents Continuous nanomaterial synthesis and gold nanocrystal production for neuroregenerative therapies | — |
| 17 | Genedit Developer of drug delivery system for genetic medicines 53Funding top 28%Talent top 28%Product top 30%Patents top 31% All 9 signals ▾Fundingtop 28% Talenttop 28% Producttop 30% Patentstop 31% Innovationtop 34% Moattop 36% Marketbottom 41% Techbottom 40% Globalbottom 40% Funding: Raised $58.5M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $58M | 18 mo ago | Series B | 39 39 → 64 (+64%) · sector median +34% | 2016 | — | 73 patents Non‑viral cationic polymers for biomolecule delivery and engineered Cpf1 guide RNAs | — |
| 18 | Terrestrial Developer of a microarray patch platform for therapeutic delivery 42Funding top 23%Talent bottom 49%Global bottom 33% All 3 signals ▾Fundingtop 23% Talentbottom 49% Globalbottom 33% Funding: Raised $57.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 42/100 | $57M | 3 mo ago | Series C | — | 2011 | — | — | — |
| 19 | Cellectar Biosciences Developer of phospholipid drug conjugates (PDC) to treat cancer | $57M | 16 mo ago | Acquired | 15 15 → 20 (+33%) · sector median +34% | 2002 | — | 128 patents Targeted cancer therapy using phospholipid‑flavagline conjugates and dosing of ether analogs | — |
| 20 | NanoViricides Targeted antiviral therapeutics 14Funding top 26%Moat top 48%Growth bottom 40%News bottom 35% All 7 signals ▾Fundingtop 26% Moattop 48% Growthbottom 40% Newsbottom 35% Globalbottom 30% Marketbottom 29% Techbottom 24% Funding: Raised $47.0M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) Moat: Editorial + unicorn rating 5/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 14/100 | $47M | 7 mo ago | Public | 17 | 2005 | — | — | — |
| 21 | Arunabio Developer of a neural exosome platform to design therapeutics for the treatment of neurodegenerative diseases 42Funding top 29%Talent bottom 49%Market bottom 47%Global bottom 37% All 5 signals ▾Fundingtop 29% Talentbottom 49% Marketbottom 47% Globalbottom 37% Newsbottom 18% Funding: Raised $33.1M across 20 rounds · 20 rounds over 9 yrs (2.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 42/100 | $33M | 10 mo ago | Series B | 40 | 2003 | — | — | — |
| 22 | Cingulate Developer of therapeutics for the treatment of ADHD | $33M | 10 mo ago | Public | 15 | 2012 | 5 signals ▼75% Earnings · Regulatory | — | 1 launch |
| 23 | Hopewell Therapeutics Provider of a synthetic lipid-based drug delivery solution | $32M | 9 mo ago | Seed | 26 | 2018 | — | — | — |
| 24 | Mercator MedSystems Developer of catheter-guided microfluid injection systems | $32M | 15 mo ago | Series D | 19 | 2000 | — | 105 patents Localized perivascular drug delivery devices for vascular disease treatment and prevention | — |
| 25 | Cristcot Pharmaceutical company developing a novel rescue drug for ulcerative colitis flares | $27M | 13 mo ago | Series C | 4 | 2008 | — | 73 patents Rectal drug delivery devices and formulations for gastrointestinal therapeutic applications | 1 job opening |
| 26 | Pulmotect Developer of therapeutics against lung infections | $25M | 21 mo ago | Series B | 4 | 2007 | — | 21 patents Immunomodulatory therapeutics targeting adaptive immunity for asthma and viral infection treatment | — |
| 27 | Xanadu Bio Delivery of nanoparticle system for mRNA and other payload delivery 53Funding top 37%Talent top 45%Global bottom 25% All 3 signals ▾Fundingtop 37% Talenttop 45% Globalbottom 25% Funding: Raised $23.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 53/100 | $23M | 10 mo ago | Series B | 5 | 2021 | — | — | — |
| 28 | Beyond Air Developer of therapeutics for multiple diseases | $22M | 20 mo ago | Public | 98 | 2011 | 8 signals ▼56% Earnings · Regulatory · Leadership | 75 patents Targeted gaseous nitric oxide delivery systems for oncology and therapeutic gas administration | 5 launchs |
| 29 | Qnovia Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals | $20M | 19 mo ago | Series B | 10 | 2018 | — | 46 patents Electronic vaping devices with integrated fluid delivery and pressure-sensing control | — |
| 30 | NeOnc Technologies Developer of drug delivery methods for pharma-based therapeutics | $19M | 10 mo ago | Public | 4 | 2008 | 16 signals Acquisition · Announcements | 48 patents Monoterpene-derived anticancer drug formulations, especially perillyl alcohol derivatives. | — |
| 31 | Therapyxinc Innovating microparticulate immune therapeutics for cancer, infectious disease, and inflammatory disorders 14Innovation top 43%Funding top 44%Product bottom 44%Global bottom 32% All 6 signals ▾Innovationtop 43% Fundingtop 44% Productbottom 44% Globalbottom 32% Techbottom 25% Marketbottom 19% Innovation: 2 product lines Funding: Raised $17.7M across 5 rounds · 5 rounds over 18 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $18M | 14 mo ago | Funding Raised | 11 | 2001 | — | — | — |
| 32 | Micron Biomedical Developer of microneedle patch technology for vaccines and drugs delivery | $17M | 17 mo ago | Series A | 11 11 → 26 (+136%) · sector median +34% | 2014 | — | — | 1 launch · 1 expansion |
| 33 | Aphios Developer of therapeutic products and enabling technology platforms for healthcare | $17M | 20 mo ago | Funding Raised | 12 | 1993 | — | 81 patents Pathogen inactivation in blood products and nanotech drug delivery for cannabinoids | — |
| 34 | Milestone Scientific Developer of computerized drug delivery injection system for dental and medical purposes | $17M | 1 mo ago | Public | 20 | 1989 | 6 signals ▼33% Earnings · Leadership | 236 patents Precision needle and catheter guidance systems for anesthetic delivery | — |
| 35 | Orlance Developer of a platform to deliver nucleic acid vaccines and related therapies | $14M | 14 mo ago | Funding Raised | — | 2016 | — | 5 patents Needle‑free drug/medical delivery devices and injection technologies. | — |
| 36 | Miist Therapeutics Developer of inhaled therapies for rapid symptom relief | $13M | 16 mo ago | Series A | — | 2022 | — | — | — |
| 37 | PanTher Therapeutics Provider of drug delivery system for cancer treatment | $12M | 15 mo ago | Series B | 47 | 2014 | — | — | — |
| 38 | RenovoRx Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs | $11M | 2 mo ago | Public | 6 | 2009 | 10 signals ▼38% Earnings · Funding | 18 patents Targeted intravascular drug delivery via vasa vasorum for cancer and pancreatic therapies | — |
| 39 | NaNotics Developer of nanomedical platform for treating major human and animal diseases 32Moat top 25%Patents top 33%Funding top 38%Talent top 38% All 7 signals ▾Moattop 25% Patentstop 33% Fundingtop 38% Talenttop 38% Innovationtop 44% Globalbottom 43% Marketbottom 23% Moat: Editorial + unicorn rating 7/10 · IP moat: 59 patents Patents: 59 patents matched (strict assignee match) · 26 filings since 2022 vs 33 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $10M | 10 mo ago | Series A | 9 | 2015 | — | 59 patents Therapeutic biomolecule inhibition and nucleic‑acid‑based scavenger particle platforms | — |
| 40 | Zyl Therapeutics Developer of hydrogel-derived nanoparticle system for topical applications 19Funding top 35%Talent top 35%Global bottom 29%Market bottom 21% All 4 signals ▾Fundingtop 35% Talenttop 35% Globalbottom 29% Marketbottom 21% Funding: Raised $9.4M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Talent: Analyst team rating 5/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 19/100 | $9M | 16 mo ago | Series B | 7 | 2017 | — | — | — |
| 41 | Vivani Developer of a drug delivery medical device for diabetes | $8M | 14 mo ago | Public | 37 37 → 36 (-3%) · sector median +34% | 2009 | 15 signals ▲200% Acquisition · Funding · Earnings | — | 2 launchs |
| 42 | NOTA Laboratories Provider of Nitric oxide-based therapies for chronic rhinosinusitis | $8M | 13 mo ago | Seed | 13 | 2014 | — | — | — |
| 43 | Aegle Therapeutics Developing extracellular vesicle therapies for debilitating rare diseases and dermatological disorders | $6M | 5 mo ago | Series A | 4 | 2013 | — | — | — |
| 44 | GelMEDIX Developer of a hydrogel drug delivery technology for ophthalmic treatment | $6M | 3 mo ago | Seed | 9 | 2019 | — | 26 patents Hydrogel biomaterials for cell encapsulation and tissue engineering applications. | — |
| 45 | Tiba Biotech Provider of fully synthetic RNA vaccine drug delivery technology | $6M | 9 mo ago | Funding Raised | 16 | 2017 | — | 58 patents Patents concentrated in health & consumer products | — |
| 46 | Phoreus Biotech Provider of a nano-delivery platform for genetic vaccines and therapeutics 14Talent top 38%Tech top 50%Funding bottom 48%Global bottom 30% All 5 signals ▾Talenttop 38% Techtop 50% Fundingbottom 48% Globalbottom 30% Marketbottom 18% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Tech: 29 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 14/100 | $4M | 7 mo ago | Seed | 6 | 2018 | — | — | — |
| 47 | Liquet Medical Provider of a platform for localized drug delivery system | $3M | 3 mo ago | Seed | 4 | 2020 | — | — | — |
| 48 | BioSapien Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents | $2M | 11 mo ago | Seed | 2 | 2018 | — | 34 patents Controlled drug‑release surgical implants for localized therapy and wound healing | — |
| 49 | PharmaIN Biopharmaceutical company pioneering subcutaneous therapies for liver disease and cancer | $2M | 10 mo ago | Seed | 17 | 2001 | — | 142 patents Targeted peptide delivery using cationic lipids and NPRA/V1A receptor agonists | 1 job opening |
| 50 | Adaptin Bio Developer of drug delivery platform for brain diseases | $1M | 5 mo ago | Public | — | 2023 | — | — | — |
Top 12 Drug Delivery companies in United States
#1
Series C · Cincinnati, Ohio · founded 2010 · 166 employees$304.3Mraised▾
Provider of a wearable drug delivery solution. The company's drug delivery device include enFuse for injectable therapies which enables a range of flexible delivery options for patients and healthcare providers, including a range of viscosities, volumes, delivery times, and sites for administration.
- Dec 2025Series C$30M
- Jan 2022Series C$215M
- Sep 2020Conventional Debt$25M
- Oct 2018Series B$50M
#2
Series B · Menlo Park, California · founded 2015 · 105 employees$342Mraised▾
Developer of precision medicines for treating lung-related diseases. The pipeline includes lead programs which includes RCT1100 an inhaled mRNA-based investigational therapy for primary ciliary dyskinesia caused by mutations in the DNAI1 gene and RCT2100 is an inhaled mRNA-based investigational therapy for cystic fibrosis. It has proprietary non-viral lipid nanoparticle platform that enables the delivery of a variety of payloads, and organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
- Sep 2025Series B$29M
- Sep 2023Series B$50M
- Jan 2023Series B$10M
- Jun 2022Series B$120M
#3
Public · Gaithersburg, Maryland · founded 2007 · 88 employees$267Mraised▾
Developer of RNA-based therapeutics for the treatment of cancer and fibrosis disease. The company has proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, to develop drug candidate pipeline which include STP122G for cardiovascular disease treatment. It also, develops pipeline of drugs for cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.
- Sep 2025Post IPO$17.7M
- Jul 2021Series E$105M
- Oct 2020Series D$105M
- Jul 2019Series C$25M
#4
Series C · Woburn, Massachusetts · founded 2011$57.3Mraised▾
Developer of a microarray patch platform for therapeutic delivery. The platform uses dissolvable tips made from advanced biomaterials for dose delivery and control. It aims to transform the delivery of therapies, offering a more convenient and comfortable patient experience. The platform seeks to eliminate the need for needles and refrigeration.
- Mar 2026Series C$57.3M
#5
Public · Livingston, New Jersey · founded 1989 · 20 employees$16.6Mraised▾
Developer of computerized drug delivery injection system for dental and medical purposes. It offers a CompuFlo system, a computer-controlled drug delivery system for epidural punctures that works using dynamic pressure sensing technology. The CathCheck system confirms the placement of the catheter and the Single Tooth Anesthesia system instrument is a computer-assisted system for local anesthesia.
- Apr 2026Post IPO$2.1M
- Jul 2015Grant (prize money)$1.5M
- May 2014PE$10M
- Mar 2005Post IPO$3M
#6
Public · Los Altos, California · founded 2009 · 6 employees$10.9Mraised▾
Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.
- Mar 2026Post IPO$10M
- Apr 2024Post IPO$11.1M
- Jan 2024Post IPO—
- May 2018Series D$7M
#7
Public · West Haven, Connecticut · founded 2005 · 17 employees$47Mraised▾
NanoViricides discovers, develops and commercializes therapeutics to treat viral infections. Nanoviricide is an antiviral agent based on the TheraCour polymeric micelle technology. This is a biomimetic platform technology has enabled the Company to rapidly develop highly effective drug candidates against a number of viral diseases. Currently developing drugs against five diseases: FluCide, a single drug against all influenzas including pandemic viruses, bird flu (H5N1), and highly pathogenic strains; HIVCide, which was found to be so effective in SCID-hu mouse model studies that it is widely believed that it could result in a “functional cure” of HIV/AIDS; HerpeCide for oral and genital herpes; DengueCide, a single drug to combat all dengue virus types; and a broad-spectrum antiviral for infections of the external eye.
- Nov 2025Post IPO$6M
- Feb 2019Post IPO$2.5M
- Jan 2014Post IPO$20M
- Feb 2013Post IPO$6M
#8
Series B · Cambridge, Massachusetts · founded 2017 · 47 employees$103.1Mraised▾
Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.
- May 2025Series B$153M
- Nov 2022Series A$45M
- Jun 2021Series A$52.1M
- May 2021Grant (prize money)$399.5K
#9
Seed · Newton, Massachusetts · founded 2019 · 9 employees$6.4Mraised▾
Developer of a hydrogel drug delivery technology for ophthalmic treatment. It offers a lead product GMX-101 a retinal pigment epithelial (RPE) cell therapy that targets Geographic Atrophy.
- Feb 2026Seed$13M
- Oct 2025Seed$542K
- Jan 2025Seed$1M
- Mar 2024Conventional Debt$1.9M
#10
Series B · Athens, Georgia · founded 2003 · 40 employees$33.1Mraised▾
Developer of a neural exosome platform to design therapeutics for the treatment of neurodegenerative diseases. The platform develops neural exosomes to cross the blood-brain barrier and enhance the body's anti-inflammatory, self-repair, and protective mechanisms to treat a range of neurodegenerative disorders. The lead candidate drug AB126 is developed to treat stroke, Parkinson's, and multiple sclerosis
- Aug 2025Grant (prize money)$400K
- Jun 2022Grant (prize money)$679.4K
- Apr 2021Series B$10.8M
- Sep 2019Grant (prize money)$4.5M
#11
Seed · Charlottesville, Virginia · founded 2020 · 4 employees$3.3Mraised▾
Provider of a platform for localized drug delivery system. The company product can be used for drug delivery in the human vascular system.
- Mar 2026Seed$75K
- Dec 2024Seed$1.1M
- Dec 2023Seed$615K
- Apr 2023Seed$405K
#12
Public · Westminster, Colorado · founded 2009 · 100 employees$72.3Mraised▾
TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.
- Apr 2025Post IPO$22M
- Dec 2024Post IPO$1000K
- Oct 2022Post IPO$15.3M
- Sep 2021Post IPO$23.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in the United States
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 9,593 United States-affiliated papers.
- Harvard University331
- University of North Carolina at Chapel Hill232
- Purdue University West Lafayette200
- Cornell University172
- Stanford University170
- Computational biology126→901
- Small molecule41→351
- Chemical space26→319
- Virtual screening24→288
- Bioinformatics14→216
- Computational biology102→599
- Docking (animal)27→275
- Drug development27→259
- Virtual screening29→235
- In silico12→211
- Computational biology75→206
- Drug development47→176
- Bioinformatics18→102
- Data science20→89
- Disease13→78
Where drug discovery is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in the United States
United States drug discovery patent filing is accelerating — 762,525 filings from 8,000 assignees (2016–2025), led by UNIV California, Genentech, Bristol Myers Squibb; annual filings 69033→70331.
- UNIV California22059
- Genentech19708
- Bristol Myers Squibb19181
- Procter & Gamble16525
- Lilly ELI15557
- Pfizer15359
- Merck Sharp & Dohme14798
- Amgen14399
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.